COSMOS HEALTH NEW DL-01 (V67A) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COSMOS HEALTH NEW DL-01 (V67A) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.60 Million ≈ $-5.37 Million USD) by net assets (€18.42 Million ≈ $21.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of COSMOS HEALTH NEW DL-01 to measure how much of total assets are equity-financed.
COSMOS HEALTH NEW DL-01 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how COSMOS HEALTH NEW DL-01's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check COSMOS HEALTH NEW DL-01 investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
COSMOS HEALTH NEW DL-01 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COSMOS HEALTH NEW DL-01 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Decade Resources Ltd
V:DEC
|
-0.028x |
|
Portage Biotech Inc
NASDAQ:PRTG
|
-2.245x |
|
Zantat Holdings Berhad
KLSE:0301
|
0.023x |
|
Pacific Horizon Investment Trust
LSE:PHI
|
0.001x |
|
Adagio Medical Holdings, Inc Common Stock
NASDAQ:ADGM
|
-0.334x |
|
Great Divide Mining Ltd
AU:GDM
|
-0.092x |
|
Melbana Energy Ltd
AU:MAY
|
-0.017x |
|
Perpetual Resources Ltd
AU:PEC
|
-0.164x |
Annual Cash Flow Conversion Efficiency for COSMOS HEALTH NEW DL-01 (2021–2025)
The table below shows the annual cash flow conversion efficiency of COSMOS HEALTH NEW DL-01 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see how much is COSMOS HEALTH NEW DL-01 worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €18.42 Million ≈ $21.54 Million |
€-8.45 Million ≈ $-9.88 Million |
-0.458x | -45.76% |
| 2024-12-31 | €24.53 Million ≈ $28.68 Million |
€-7.72 Million ≈ $-9.02 Million |
-0.315x | +27.49% |
| 2023-12-31 | €36.04 Million ≈ $42.14 Million |
€-15.64 Million ≈ $-18.28 Million |
-0.434x | -15.69% |
| 2022-12-31 | €39.66 Million ≈ $46.36 Million |
€-14.87 Million ≈ $-17.39 Million |
-0.375x | +76.86% |
| 2021-12-31 | €4.38 Million ≈ $5.12 Million |
€-7.10 Million ≈ $-8.30 Million |
-1.621x | -- |
About COSMOS HEALTH NEW DL-01
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company offers prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It als… Read more